SGLT2 Inhibitors – The New HF Therapies on the Block

Published: 25 August 2020

  • Views:

    Views Icon 341
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


In this Educational Symposium from the e-SPACE Heart Failure Global Web-Conference, Subodh Verma, Nikolaus Marx and Shelley Zieroth discuss SGLT2 inhibitors covering their history, a clinical perspective into what we have learned about them and how future trials might affect clinical practice. 

These videos were funded by an unrestricted educational grant from Boehringer Ingelheim & Eli Lilly and Company.

Learning objectives

  • Raise Awareness of SGLT2 Inhibitors as Cardiovascular Therapies With Cardio–Renal Benefits
  • Highlight Appropriate Patients for Initiation of an SGLT2 Inhibitor and Share With Cardiologists the Well-Established Safety Profile and Clinical Considerations for SGLT2 Inhibitor Treatment
  • Inform Cardiologists of the Current Evidence and Ongoing Trials for SGLT2 Inhibitors in Patients With HF


  • 5 mins - Welcome & introduction - Subodh Verma
  • 15 mins - A brief history of SGLT2 inhibitors - Subodh Verma
  • 15 mins - What have we learned about SGLT2 inhibitors? A clinical perspective - Nikolaus Marx
  • 15 mins - How might future trials affect how I might treat my patients? - Shelley Zieroth
  • 10 mins - Faculty discussion (pre-recorded) - All Faculty
  • Close - Subodh Verma
  • Live Q&A and discussion - All Faculty

More from this programme

Part 1

Welcome & Introductions

Part 2

A Brief History of SGLT2 Inhibitors

Part 3

What Have We Learned About SGLT2 Inhibitors? A Clinical Perspective

Part 4

How Might Future Trials Affect How I Treat My Patients?

Part 5

Panel discussion

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

Director, Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.

She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile